Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington’s Disease

Marta Tomczyk 1,2,*, Alicja Braczko 1, Paulina Mierzejewska 1, Magdalena Podlacha 2, Oliwia Krol 1, Patrycja Jablonska 1, Agata Jedrzejewska 1, Karolina Pierzynowska 1,2, Grzegorz Wegrzyn 2, Ewa M. Slominska 1 and Ryszard T. Smolenski 1,*.  

1 Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland  
2 Department of Molecular Biology, University of Gdansk, 80-308 Gdansk, Poland  
* Correspondence: marta.tomczyk@gumed.edu.pl (M.T.); rt.smolenski@gumed.edu.pl (R.T.S.)

Abstract: Huntington’s disease (HD) is a rare neurodegenerative disease that is accompanied by skeletal muscle atrophy and cardiomyopathy. Tissues affected by HD (central nervous system [CNS], skeletal muscle, and heart) are known to suffer from deteriorated cellular energy metabolism that manifests already at presymptomatic stages. This work aimed to test the effects of peroxisome proliferator-activated receptor (PPAR)-γ agonist—rosiglitazone on grip strength and heart function in an experimental HD model—on R6/1 mice and to address the mechanisms. We noted that rosiglitazone treatment lead to improvement of R6/1 mice grip strength and cardiac mechanical function. It was accompanied by an enhancement of the total adenine nucleotides pool, increased glucose oxidation, changes in mitochondrial number (indicated as increased citric synthase activity), and reduction in mitochondrial complex I activity. These metabolic changes were supported by increased total antioxidant status in HD mice injected with rosiglitazone. Correction of energy deficits with rosiglitazone was further indicated by decreased accumulation of nucleotide catabolites in HD mice serum. Thus, rosiglitazone treatment may not only delay neurodegeneration but also may ameliorate cardio- and myopathy linked to HD by improvement of cellular energetics.

Keywords: Huntington’s disease; myopathy; cardiomyopathy; rosiglitazone; molecular mechanisms; therapy; energy metabolism

1. Introduction

Huntington’s disease (HD) is a rare neurodegenerative disease that is known to primarily affect the central nervous system. The genetic cause of HD is the occurrence of multiple repeats of the CAG nucleotide sequence within the huntingtin gene (HTT) localized on chromosome 4, which results in the elongation of the polyglutamine stretch in the HTT protein [1]. The elongation of the polyglutamine stretch in exon 1 HTT leads to the formation of insoluble huntingtin aggregates, which are observed in both the early and advanced stages of the disease [2,3]. Aggregates of the mutated form of HTT (mHTT) have been identified not only in the brain but also outside the central nervous system (CNS), e.g., in skeletal muscle [3–5]. Interestingly, mHTT is absent in the HD-affected heart [6,7]. It has been shown that HD patients suffer from reduced (by about 50%) muscular strength compared to healthy controls [8]. Besides skeletal muscle pathology, multiple epidemiological studies have shown that heart failure is the second leading cause of death in HD patients [9,10]. Similar findings were observed in preclinical HD models [11]. HD mice models were characterized by skeletal muscle atrophy and altered ultrastructure of transverse tubules in skeletal muscle fibers [12,13]. mHTT formation in skeletal muscle leads to defects, such as myofiber size reduction or type switching [12,14–17]. HD animal models reaffirmed cardiac pathological events noted in HD patients, such as variations in the heart rate and cardiac remodeling [7,18,19]. Moreover, heart contractile dysfunctions,
which might be a part of dilated cardiomyopathy were noted [7]. Thus, nowadays HD is considered as a multisystem disorder [11,20].

HD-affected CNS and non-CNS tissues were characterized by defects in energy metabolism [21]. The striatum mitochondrial oxidative metabolism investigation underlined the selective defect of glycolysis in early and clinical symptoms in HD patients [22]. In a few independent studies of the striatum of mHTT knock-in mice, HD patients’ post-mortem brains, and lymphoblasts, the adenosine-5′-triphosphate (ATP)/adenosine-5′-diphosphate (ADP) ratio was reduced as a consequence of mHTT aggregation [23–25]. A decreased ATP/ADP ratio was found also in mHTT-containing striatal cells, which were linked to increased Ca\(^{2+}\) influx through N-methyl-D-aspartate (NMDA) receptors. Interestingly, the disrupted ATP/ADP ratio was normalized by blocking Ca\(^{2+}\) influx [26]. Deteriorations in energy metabolism occur also in HD-affected skeletal muscle [27]. It has been noted that the skeletal muscles of HD patients are characterized by dysfunction of oxidative metabolism [28]. Moreover, muscle ATP/phosphocreatine and inorganic phosphate levels were significantly reduced in both symptomatic and presymptomatic HD subjects [29]. Previously, we have noted that R6/2, as well as HdhQ150, two well-established HD mice models, exhibited decreased ATP, ADP, and adenosine-5′-monophosphate (AMP) concentrations in three different skeletal muscle tissues—extensor digitorum longus, tibialis anterior, and soleus. Moreover, a significant reduction of phosphocreatine (PCr) and creatine (Cr) levels and the PCr/Cr were noted [17]. Similar changes were observed in HD mice models’ hearts. We highlighted decreased concentrations of ATP and phosphocreatine as well as diminished ATP/ADP ratios [30].

Interestingly, as mentioned above, energy metabolism deterioration manifests not only in the advanced stages of the disease but also in the presymptomatic. It could be suggested that energy deficit is likely to be an early phenomenon in the cascade of events leading to HD pathogenesis. Moreover, impaired bioenergetics in HD likely represent downstream effects of both an mHTT toxic gain-of-function and an HTT loss-of-function [21]. Thus, therapeutic strategies include compounds that directly correct disrupted ATP levels in affected HD CNS as well as non-CNS tissues might be an interesting therapeutic target. Nevertheless, compounds such as the coenzyme Q10 or creatinine were widely tested and even investigated in clinical trials, but the results were not promising [31].

An alternative might be the application of peroxisome proliferator-activated receptors (PPARs) agonists, which have already undergone preclinical studies for the treatment of CNS, cardiovascular as well as skeletal muscle diseases. PPARs belong to the group of nuclear receptors that activate or repress target genes as heterodimers with retinoic X receptors (RXR). PPARs family included: PPAR alpha (PPAR\(^\alpha\)), PPAR beta/delta (PPAR\(^\beta/\delta\)), and PPAR gamma (PPAR\(^\gamma\)) [32]. Different types of cells exhibited various expressions of PPARs; thus, the outcome of its activation might be different in various tissues [33]. In 2016, the PPAR delta receptor agonist KD3010 was tested in the HD N171-82Q mouse model. Study revealed improved motor function, reducing the progression of the neurodegenerative process, and longer survival of treated animals [34]. Nevertheless, this study was focused mainly on the evaluation of CNS function improvement. Thus, our work for the first time highlighted the effect of PPAR agonist treatment on HD mouse model grip strength, cardiac function, and HD-affected skeletal muscle and heart metabolism.

2. Materials and Methods
2.1. Animal Maintenance and Treatment

All experiments were conducted following the Guide for the Care and Use of the Laboratory Animals published by the European Parliament, Directive 2010/63/EU, and were approved by the local bioethical committee for the Medical University of Gdansk. Animals were maintained on a 12:12 h light-dark cycle at 25 °C, 30–40% humidity, and were provided with free access to water and a standard chow diet (Morawski, Kcynia, Poland). R6/1 (n = 30) aged 21 weeks old and C57BL/6J (n = 11) as WT mice were used in the study. R6/1 mice (n = 12) were treated daily for six weeks with 10 mg/kg of rosiglitazone
Cells 2022, 11, 2662

(Sigma-Aldrich, St. Louis, MO, USA) (dissolved in 0.09% DMSO) or 0.09% DMSO (Sigma-Aldrich, St. Louis, MO, USA) administered intraperitoneally [35].

2.1.1. Forelimb Grip Strength Measurement

Forelimb grip strength was measured by a grip strength meter (GSM Grip strength meter, Ugo Basile, Gemonio VA, Italy) as described earlier [36]. Briefly, the animal was held on the apparatus so that only the forelimb paws grasped the specially designed mouse flat mesh assembly. Then, the mouse was pulled back until its grip was broken, which was recorded from a digital display. The maximum values were used for analysis. Forelimb and maximal muscle strength were obtained as values of GF (gram-force) and normalized to body weights as “g/g mouse body weight.”

2.1.2. Echocardiography

Echocardiographic examination was performed with a high-resolution ultrasound system (Vevo 1100, VisualSonics Inc, Toronto, Ontario, Canada) [37]. Mice were anesthetized with ketamine (Biowet Pulawy, Pulawy, Poland) (100 mg/kg) and xylazine (Biowet Pulawy, Pulawy, Poland) (10 mg/kg) intraperitoneally (i.p.), then their chest hair was removed and mice were placed on a heating pad. The probe (70 MHz) was placed over the anterior chest wall and directed to the ascending aorta in 2D mode. Then the mode was switched to Doppler flow velocity. Stroke Volume (SV), Cardiac Output (CO), Left Ventricular mass (LVmass), Ejection Fraction (EF), and Fractional shortening (FS) were recorded.

2.1.3. Analysis of Cardiac and Skeletal Muscle Glucose Usage

Analysis of cardiac and skeletal muscle glucose usage was performed within the method described before [30,38]. D-glucose-1,6-13C2 (Sigma-Aldrich, St. Louis, MO, USA) was administrated in the subcutaneous injection of a 1.8 mg/g body weight dose. Moreover, blood samples were collected from the tail vein before and after 30, 60, and 90 min of 13C2 glucose administration. Next, after animal anesthesia, heart and skeletal muscle were rapidly excised (after 90 min), and freeze clamped (after animal intubation and under artificial ventilation).

Hearts were placed for 24 h in a freeze dryer (Modulyo, Thermo Electron Corporation, Waltham, MA, USA) at −55 °C, and then were extracted with 0.4 M perchloric acid (Sigma-Aldrich, St. Louis, MO, USA) in a 1:25 ratio, followed by neutralization with 2 M KOH (Sigma-Aldrich, St. Louis, MO, USA). Supernatants (obtained from centrifugation at 4 °C, 14,000 RPM/min for 10 min) were analyzed by LC/MS.

Blood extraction was performed using ice-cooled acetone (Sigma-Aldrich, St. Louis, MO, USA) in a 1:3 ratio. Next, samples were placed in ice for 15 min and centrifuged at 4 °C, 14,000 RPM/min for 10 min. This was followed by drying in a vacuum concentrator (JW Electronic, Warsaw, Poland) and sediments were dissolved in high-purity water (Nanopure—ultrapure water system, Barnstead, Thermo, Waltham, MA, USA) and analyzed with LC/MS.

The heart extracts were analyzed by LC/MS using a TSQ-Vantage triple quadrupole mass detector (Thermo, Waltham, MA, USA), linked to a Surveyor chromatography system (Thermo, Waltham, MA, USA) in positive heated electrospray ionization with fragmentation mode (Tandem MS), monitoring 13C isotopic enrichment of fragments containing C3 of alanine or C4 of glutamate. The 13C glucose enrichment in blood was measured using liquid chromatography-mass spectrometry—an LCQ-Deca XP mass detector (Thermo Finnigan, San Jose, CA, USA). Fragments containing 12C and 13C glucose were detected in negative electrospray ionization with the selected ion monitoring (SIM) mode for 12C glucose m/z 178.00–179.40 and m/z 179.00–180.40 for D-glucose-1,6-13C2.

2.1.4. Mice Tissues and Serum Collection

Tissues and serum for further analysis were collected after mice anesthesia with a ketamine/xylazine mixture (Biowet Pulawy, Pulawy, Poland) (50 mg/kg + 5 mg/kg)
and artificial ventilation. Blood was collected from inferior vena cava (IVC). For serum collection, blood was centrifuged at 2000 RPM for 4 min. Mice heart and skeletal muscle were also isolated.

2.2. Measurement of Total Adenine Nucleotides Pool, Phosphocreatine and Creatine, and Nicotinamide Dinucleotides

Hearts and skeletal muscle (soleus) were prepared and analyzed with the high-pressure liquid chromatography (HPLC) method as previously described [30].

2.3. Investigation of Cardiac and Skeletal Muscle Mitochondrial Chain Complexes Activities

Mitochondria were isolated from the soleus muscle and heart, and prepared based on the previously described procedure [36,39]. Analysis was performed by Seahorse Metabolic Flux Analyzer (Agilent Technologies, Santa Clara, CA, USA). For electron flow experiments, isolated mitochondria were diluted in cold MAS buffer (enriched with 10 mM pyruvate (Sigma-Aldrich, St. Louis, MO, USA), 2 mM malate (Sigma-Aldrich, St. Louis, MO, USA), and 4 µM FCCP (Sigma-Aldrich, St. Louis, MO, USA). A mitochondrial suspension of 25 µL was placed into Seahorse plate wells and centrifuged at 2000×g for 15 min at 4 °C. The concentration of mitochondrial protein was 6 µg per well. After centrifugation, 180 µL of prewarmed MAS buffer supplemented with pyruvate, malate, and FCCP was added to each well, and the plate was then placed into a non-CO₂ incubator for 8 min. The Seahorse cartridge was filled with the following reagents: 2 µM Rotenone (Sigma-Aldrich, St. Louis, MO, USA), 2 mM succinate (Sigma-Aldrich, St. Louis, MO, USA), 4 µM Antimycin (Sigma-Aldrich, St. Louis, MO, USA), and a mix of 10 mM ascorbate (Sigma-Aldrich, St. Louis, MO, USA) and 100 µM TMPD (Sigma-Aldrich, St. Louis, MO, USA).

2.4. Evaluation of Cardiac and Skeletal Muscle Citric Synthase Activity

Citric synthase activity (in soleus muscle and heart) was measured within the assay kit (Sigma-Aldrich, St. Louis, MO, USA). The activity of the enzyme is measured by following the color of 5-thio-2-nitrobenzoic acid (TNB), which is generated from 5,5′-Dithiobis-(2-nitrobenzoic acid) (DTNB) present in the reaction of citrate synthesis, and caused by the deacetylation of Acetyl-CoA. Citric synthase activity was presented as µmol/mL/min.

2.5. Measurement of Nucleotides Catabolites in Serum

Mice serum was extracted with 1.3 M perchloric acid (Sigma-Aldrich, Burlington, MA, USA) (1:1 ratio). Levels of nucleotides were measured by a reverse-phase high-pressure liquid chromatography (RP-HPLC) method using the liquid chromatography (LC) system (Agilent Technologies 1100 system, Agilent Technologies Inc., Santa Clara, CA, USA), as described previously [15,30]. Results are presented as µmol/L.

2.6. Analysis of Total Plasma Antioxidant Status

The total antioxidant status (TAOS) in plasma was measured by the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) assay, which was based on the capacity of plasma to scavenge the ABTS⁺ radical [40]. Briefly, the relative inhibition of ABTS⁺ formation, after the plasma addition, is proportional to the antioxidant capacity of the sample. For the measurement, plasma was diluted with 180 µL phosphate buffer (0.076 M NaH₂PO₄ (POCH, Gliwice, Poland) + 0.23 M Na₂HPO₄ (Sigma-Aldrich, Burlington, MA, USA) in pure water), and then it was incubated for 10 min at room temperature in a 96-well plate with a 5 µL reaction mixture containing 7 mM ABTS (Sigma-Aldrich, Burlington, MA, USA) and 2.45 mM potassium persulfate (Sigma-Aldrich, Burlington, MA, USA) (in phosphate buffer: 0.22 M NaH₂PO₄ (POCH, Gliwice, Poland) + 0.37 M Na₂HPO₄ (Sigma-Aldrich, Burlington, MA, USA)) solved in pure water. The absorbance in the test and control samples (saline instead of plasma) was read at 630 nm. Results expressed as percentage inhibition of the reaction were calculated as follows: TAOS [%] = 100 × (Ac − At)/Ac, where Ac is the absorbance of the control sample absorbance, and At is the test sample absorbance.
2.7. Investigation of Serum-Free Fatty Acids and Blood Glucose Levels

The free fatty acids (FFA) concentration in serum was measured using a commercial colorimetric assay kit (Wako NEFA C test kit; Wako Chemicals, Neuss, Germany). Serum was collected after 24 h starvation. Random blood glucose levels were measured with a glucometer (Accu check Active, Roche Diabetes Care, F. Hoffmann-La Roche Ltd., Basel, Switzerland). Blood drop was collected from the tail vein of non-starved mice.

2.8. Statistical Analysis

Statistical significance was evaluated using Student’s t-test for comparatives of two groups. A value of $p < 0.05$ was used to denote statistical significance, and the results are expressed as mean ± SEM. All statistics were carried out using GraphPad Prism 5.00 (GraphPad Software, San Diego, CA, USA).

3. Results

3.1. Rosiglitazone Improved Grip Strength and Cardiac Function in an HD Mouse Model

Previous experimental research that investigated the cardiac and skeletal muscle function in Huntington’s disease (HD) examined those mainly other than R6/1 HD mice models (R6/2, HdhQ150, or N171-82Q). Thus, to ensure that the investigated HD mouse model exhibited any changes in skeletal muscle and cardiac functionality, we assessed the forelimb grip strength and as well as cardiac function parameters (stroke volume, ejection fraction, fractional shortening, cardiac output, and left ventricular mass) in R6/1 in comparison to healthy controls. Similar to other HD mice models, the R6/1 mice model also exhibited a reduction of forelimb grip strength as well as normalized grip strength (Supplement Figure S1). Furthermore, significant reduction in ejection fraction, fractional shortening, cardiac output as well as left ventricular mass relative to wild-type (WT) were noted (Supplement Figure S2). That results suggested the presence of serious depletion of grip strength and cardiac function.

One of the main goals of our study was to investigate the influence of rosiglitazone on HD mouse model skeletal muscle functionality. Thus, we measured the forelimb grip strength and normalized grip strength (force normalized for mouse body weight) in R6/1 and R6/1 mice treated with rosiglitazone. We found no changes in body weight in peroxisome proliferator-activated receptor (PPAR) agonists treated mice in comparison to non-treated HD mice, while maximum, as well as normalized grip strength evaluation, indicated higher values of these parameters in HD treated with rosiglitazone (Figure 1A–C).

![Figure 1](image_url)

**Figure 1.** Improved grip strength in R6/1 mice treated with rosiglitazone. (A) Maximum forelimb grip strength. (B) Bodyweight (C) Normalized forelimb grip strength (maximum forelimb grip strength/g of body weight) in R6/1 (HD) and R6/1 with rosiglitazone treated mice (HD + Rosiglitazone). Results presented as mean ± SEM, n = 5–6, *$p < 0.05$, ***$p < 0.001$. The red dotted lines present the mean value of the investigated parameter in control, C57BL/6J mice (adapted from supplementary material data).

We examined also the R6/1 mice’s heart function after rosiglitazone treatment (representative echocardiograms in Supplement Figure S3). We noted tendencies in the improvement of stroke volume (SV), cardiac output, and ejection fraction in HD mice treated with rosiglitazone and no changes in left ventricular mass in comparison to HD control (treated...
with 0.09% DMSO) (Figure 2A–D). Interestingly, we found the statistically confirmed improvement of fractional shortening in the HD mouse model injected with investigated PPAR agonist (Figure 2E).

Figure 2. Huntington’s disease (HD) mouse model heart function improvement after rosiglitazone treatment (A) Stroke volume (SV), (B) Cardiac output, (C) Ejection fraction, (D) Left ventricle mass, (E) Fractional shortening in R6/1 (HD) and R6/1 with rosiglitazone treated mice (HD + Rosiglitazone). Results presented, n = 4–6, * p < 0.05. The red dotted lines present the mean value of the investigated parameter in control, C57BL/6J mice (adapted from supplementary material data).

3.2. Rosiglitazone Enhanced Skeletal Muscle and Cardiac Glucose Usage in an HD Mouse Model

To unravel the source of the noticed skeletal muscle as well as cardiac functionality improvement, we evaluated the in vivo glycolytic and oxidative metabolism of labeled $^{13}$C glucose. Metabolite tracking ($^{4-13}$C glutamate and $^{3-13}$C alanine) after $^{13}$C glucose administration was previously extensively studied by our group [38]. Theoretical assumptions, supported by experimental studies, indicate that after $^{13}$C glucose administration, the heart accumulates $^{3-13}$C pyruvate in proportion to the fraction of glycolytic substrate, supplied by exogenous glucose relative to alternative unlabeled substrate sources (e.g., endogenous glycogen) and $^{4-13}$C α-ketoglutarate in proportion to the fraction of tricarboxylic acid (TCA) cycle carbon flux supported by flux through pyruvate dehydrogenase (PDH), relative to other acetyl-CoA sources (e.g., free fatty acids (FFA)). It has to be mentioned that $^{3-13}$C pyruvate, as well as $^{4-13}$C α-ketoglutarate, were present in small quantities in the heart, but occur in isotopic equilibrium with tracked $^{3-13}$C alanine and $^{4-13}$C glutamate [41]. Thus,
the measurement of myocardial or skeletal muscle 3-13C alanine/12C alanine (13C alanine enrichment) and 4-13C glutamate/12C glutamate (13C glutamate enrichment) in steady-state 13C glucose enrichment in the blood allows for the estimation of the contribution of circulating glucose to myocardial glycolytic and oxidative flux.

We observed no changes in 13C alanine enrichment in skeletal muscle as well as in heart to 13C glucose enrichment in the mouse blood ratio (Figure 3A,D). On the other hand, we noted an increased 13C glutamate/13C glucose ratio and 13C glutamate/13C alanine ratio in skeletal muscle and heart in the R6/1 mouse model treated with rosiglitazone relative to HD treated with 0.09% DMSO (control), which indicates enhanced glucose oxidation as well as its overall use in cardiac and skeletal muscle metabolism (Figure 3B,C,E,F).

Figure 3. Increased glucose usage in cardiac and skeletal muscle metabolism in Huntington’s disease (HD) mouse model treated with rosiglitazone. (A) 13C alanine enrichment in heart/13C glucose enrichment ratio in the blood, (B) 13C glutamate enrichment in heart/13C glucose enrichment ratio in the blood, (C) 13C glutamate/13C alanine enrichment ratio in the heart, (D) 13C alanine enrichment in skeletal muscle/13C glucose enrichment ratio in the blood, (E) 13C glutamate enrichment in skeletal muscle/13C glucose enrichment ratio in the blood, (F) 13C glutamate/13C alanine ratio enrichment in the skeletal muscle of R6/1 (HD) and R6/1 with rosiglitazone treated mice (HD + Rosiglitazone). Data presented; n = 5; * p < 0.05, *** p < 0.001. Due to the methodological inability to compare the obtained values with previous experiments, values from control experiments (wild-type mice) are not shown. Nevertheless, the comparison of glucose usage in cardiac and skeletal muscle metabolism between control and HD mice models was already published in our two previous studies [17,30].

Additionally, we assessed the serum-free fatty acids (FFA) as well as blood glucose concentration (Supplementary Figure S4). We found that HD mice treated with PPAR agonist were characterized by reduced blood glucose levels in comparison to non-treated mice. In the case of FFA, we found that HD mice injected with rosiglitazone do not exhibit statistically significant changes in this parameter relative to HD non-treated mice.

3.3. Rosiglitazone Improved Cardiac and Skeletal Muscle Adenine Nucleotides Pool

Further analysis tested whether rosiglitazone may affect overall skeletal muscle and cardiac energy metabolism. While accurate quantitative analysis of unstable metabolites such as adenosine-5’-triphosphate (ATP) and phosphocreatine was not possible due to limitations of the tissue collection procedure we were able to collect data on total pools of
relevant metabolites. We noted that total cardiac and skeletal muscle adenine nucleotides pools were elevated in rosiglitazone-injected mice (Figure 4A,D). Similar increases were found in total creatine pools (Figure 4B,E). On the other hand, there were no changes in the total cardiac and skeletal muscle NAD\(^+\) and NADH pool (Figure 4C,F).

**Figure 4.** Enhanced total adenine nucleotides and total phosphocreatine creatine pools in hearts and skeletal muscles of Huntington’s disease (HD) mouse model treated with rosiglitazone. Total adenine nucleotides pool in hearts (A) and skeletal muscle (D), total phosphocreatine and creatine pool in hearts (B) and skeletal muscle (E), and total NAD\(^+\) and NADH pools in hearts (C) and skeletal muscle (F) in R6/1 (HD) and R6/1 with rosiglitazone treated mice (HD + Rosiglitazone). Results presented as mean ± SEM, \(n = 4–6\), * \(p < 0.05\), ** \(p < 0.01\), *** \(p < 0.001\). The red dotted lines present the mean value of the investigated parameter in control, C57BL/6J mice (adapted from our previous works [17,42]).

3.4. Rosiglitazone Led to Cardiac and Skeletal Muscle Mitochondria Functionality Changes

The initial step of this part of our research was the examination of oxygen consumption rate (OCR) in coupled and un-coupled cardiac and soleus mitochondria of R6/1 (HD) as well as control WT mice. Moreover, we assessed the activities of mitochondrial complex I (with pyruvate, malate, and FCCP), II (after rotenone and succinate addition), and complex IV (after addition of TMPD and ascorbate) in isolated mitochondria.

We did not observe differences in OCR between coupled cardiac and soleus muscle mitochondria isolated from HD and WT mice at any measurement points (Supplementary Figure S5A,C). The level of respiration in isolated cardiac mitochondria in state 2, state 3 ADP, state 4o, and state 3u were similar in both strains (Supplementary Figure S5B). On the other hand, examination of mitochondrial respiration states in soleus muscle highlighted the reduced state 3u (controlled exclusively by substrate oxidation, its reduction might suggest dysfunction in respiratory chain components, substrates translocases, or dehydrogenases) (Supplementary Figure S5D). Interestingly, evaluation of R6/1 mice cardiac and soleus muscle mitochondrial OCR and complexes activities in an uncoupled state revealed complex I hyper-activation in comparison to WT (Supplementary Figures S6A,B and S7A,B). No changes in cardiac and skeletal muscle mitochondrial complex IV respiration were found between HD and control mice (Supplementary Figures S6D and S7D). Nevertheless, some difference was found between those investigated tissues. Indeed, R6/1 mice heart exhibited increased mitochondrial complex II respiration (Supplementary Figure S6A,C), while soleus muscle exhibited opposite reduced tendency (Supplementary Figure S7A,C).
Next, we evaluated the activity of citric synthase (CS, the indicator of mitochondria amount) and reactive oxygen species levels (ROS, the indicator of oxidative stress) in the hearts and soleus of HD and control mice. We found no changes in CS activity and increased ROS levels in R6/1 mice’s hearts and skeletal muscle in comparison to control mice (Supplementary Figure S8A–D). Results ensure the presence of mitochondrial functionality changes in HD-affected heart and skeletal muscle in investigated HD mice model.

It is well known that rosiglitazone may improve mitochondrial number and metabolism. Thus, we aimed to evaluate the mitochondrial oxidative chain complexes’ respiration and activities in hearts and mitochondria-rich, red soleus muscle, isolated from HD mice treated with rosiglitazone as well as non-treated HD mice. There were no changes in complex II and complex IV respiration, while reduced complex I respiration in hearts and soleus of R6/1 treated with PPAR agonist (HD + Rosiglitazone) relative to R6/1 (HD) were noted (Figure 5A,B,D,E).

To investigate the effect of rosiglitazone on mitochondrial biogenesis in HD-affected tissues (heart and skeletal muscle), we assessed the activity of citric synthase. Interestingly, we noted elevated activity of this enzyme in investigated tissues isolated from HD mice treated with rosiglitazone in comparison to non-treated HD mice (Figure 5C,F).

3.5. Rosiglitazone Abolished Changes in Energy Deficits Biomarkers and Improved Total Antioxidant Status in HD Mouse Model Serum

Improvement of energy metabolism may lead to changes in nucleotides’ catabolite profile in serum. Thus, the next step of our research was the evaluation of the concentration...
of uric acid, hypoxanthine, and inosine in the serum of R6/1 mice treated with rosiglitazone. We found reduced levels of all investigated nucleotide catabolites in HD mice injected with PPAR agonist in comparison to non-treated mice (Figure 6A–C).

4. Discussion

This study highlighted that the rosiglitazone treatment improves grip strength and cardiac function in Huntington’s disease (HD) mouse model R6/1 (Figure 7). These functional changes were accompanied by enhanced total adenine nucleotide and total creatine pools, increased glucose oxidation, changes in mitochondrial number (indicated as increased citric synthase activity), and reduction of mitochondrial complex I activity. Correction of energy deficits with rosiglitazone abolished, as noted in our previous research, the accumulation of nucleotide catabolites in HD mice serum [30]. Moreover, enhancement of energy metabolism and changes in mitochondrial complex I lead to improvement of oxidative balance highlighted as an increased total antioxidant status in HD mice injected with rosiglitazone.
Rosiglitazone is a synthetic agonist of peroxisome proliferator-activated receptor (PPAR)-γ, which is commonly used to reverse insulin resistance in patients with type II diabetes [43]. Interestingly, it has also been tested as a neuroprotective agent in HD, where it significantly attenuated toxicity induced by mutant huntingtin (mHTT) in striatal cells [44]. Rosiglitazone treatment also significantly reduced mHTT aggregates in the mHTT expressing neuroblastoma cell line [45]. Moreover, administration of rosiglitazone significantly improved motor function, rescued brain-derived neurotrophic factor (BDNF) deficiency in the cerebral cortex, and prevented loss of orexin-A-immunopositive neurons in the hypothalamus of N171-82Q HD mice [35]. Similar results were also noted in the HD rat model (injected with quinolinic acid) treated with rosiglitazone [46]. However, our study for the first time indicated that PPAR-γ agonist treatment of the HD mouse model also improved skeletal muscle as well as heart functionality. Although PPAR-γ expression in skeletal muscle and the heart is relatively small, there are studies indicating that these receptors may play an important role in its metabolism and function [47,48]. Treating fibromyalgia (multisystem failure process involving the immune, musculoskeletal, and central nervous system) in rats with PPAR-γ agonist, pioglitazone resulted in a significant improvement of skeletal muscle functions, reduced fatigability, and rapid recovery from fatigue [49], which is consistent with our results. Blocking the PPAR-γ pathway, though administration of GW9662, counteracted pioglitazone’s protective effects [49]. Interestingly, experimental studies have also shown a reduction in the level of peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α), one of the proteins activated by PPAR-γ in skeletal muscles of HD mice models as well as HD patients [50]. Additionally, the pharmacological activation of this co-activator led to the increased expression of skele-
tal muscle fiber proteins that suggested an important role of the PPAR pathway in the development of HD-related myopathy [51]. Moreover, rosiglitazone treatment seems to have an impact also on the cardiovascular system [43]. Consistently with our observation, rosiglitazone administration led to improvement of cardiac function (contractile dysfunction and the protection of myocardial injury during ischemic/reperfusion) in different animal models [52–54]. Nevertheless, opposite findings have also been reported. Growing evidence has demonstrated adverse effects of rosiglitazone, including increased risk of acute myocardial infarction and heart failure, which was one of the causes of its withdrawal from EU countries [55,56]. Besides its controversy, rosiglitazone seems to be an interesting therapeutic tool in HD due to unique metabolic alterations reported in this disease.

Indeed, our previous research indicated that HD cardio- and myopathy were linked with deficits in energy metabolism [17,30]. We noted that HD mice models exhibited decreased glucose oxidation in skeletal muscle and heart. This change may reduce production capacity for adenosine-5′-triphosphate (ATP), especially if combined with reduced oxygen supply. Glucose is a better substrate for energy supply ensuring cell survival. Its oxidation generates more ATP molecules concerning oxygen consumption than other metabolic fuels. Thus, increasing glucose oxidation in HD-affected skeletal muscle and heart may result in an improvement of its function. PPAR agonists could induce such an effect. Indeed, How et al. noted that rosiglitazone treatment diminished cardiac fatty acids and increased cardiac glucose oxidation in diabetic mice [57]. Rosiglitazone enhanced also glucose oxidation, and thus its overall use in metabolism in our study. Similar to our results, it was accompanied by reduced blood glucose levels caused by increased whole-body glucose uptake and its reduced hepatic release [57,58]. One may conclude that rosiglitazone treatment may help cardiac and skeletal muscle function in HD mice by treating impaired glucose homeostasis that may develop at later stages of the disease instead of directly targeting primary HD defects [59]. Although R6/1 displayed some signs of impaired glucose tolerance (including abnormal glucose handling and higher glucose plasma and insulin levels in the glucose challenge), it did not manifest as diabetes due to normal peripheral insulin sensitivity. Moreover, the fasting plasma glucose levels were similar to the values in wild-type mice, as described by different investigators; thus, this experimental model is recognized as a nondiabetic HD mouse model [59–61]. Interestingly, the glucose concentration reduction after rosiglitazone was also observed in non-diabetic individuals [58]. This suggests that rosiglitazone treatment could be beneficial for skeletal muscle and cardiac metabolism in HD in a way that is independent of diabetic status.

As mentioned earlier, PPAR-γ is not highly expressed in cardiac and skeletal muscle tissue, and so the effect of rosiglitazone on substrate metabolism might be most likely indirect to the changes in cardiac substrate supply, rather than a direct effect of PPARγ on cardiac or skeletal muscle. Nevertheless, our study indicated that this metabolic shift resulted in improvement of total adenine nucleotides as well as total phosphocreatine and creatine pool in R6/1 mice model skeletal muscle and heart. Moreover, energy deficits improved via rosiglitazone abolished also the massive elevation in nucleotides catabolites (inosine, hypoxanthine, and uric acid) concentration in HD mouse serum observed in our previous research [30]. Indeed, we found an increase in inosine, hypoxanthine, xanthine, and uric acid in the sera of the HD murine models. More importantly, we found also that hypoxanthine levels were elevated also in the plasma of symptomatic HD patients and correlated with HD progression parameters [30]. We suggested earlier that catabolites that we observed in sera were released by the affected heart and/or skeletal muscle tissues, which is in the line with the current study.

Changes in energy metabolism in HD-related myopathies were linked with disruption in mitochondrial structure [50,62,63]. It has been reported that rosiglitazone treatment increases mitochondrial biogenesis in the brain and others mice tissues [44,64,65]. Indeed, we also found the increased activity of citrate synthase, a commonly used marker of mitochondrial abundance, in HD mouse model skeletal muscle and hearts treated with rosiglitazone [66]. Mitochondrial dysfunction in HD was linked also to its functionality...
changes including disruption of mitochondrial metabolism, calcium overload, and thus oxidative stress induction [21,67–70]. It has been shown that mHTT intracellular aggregation leads to increased reactive oxygen species (ROS) production [71]. ROS play also an important role in skeletal muscle atrophy and heart failure [72–74]. Abnormalities of superoxide dismutase activity and glutathione peroxidase, antioxidant enzymes involved in ROS breakdown, were also found in the HD-affected cardiac mitochondria [75]. Interestingly, we noted also an increased ROS level in R6/1 mice’s hearts and skeletal muscle.

It is well known that mitochondrial complex I and III, but especially complex I, are considered to be the main sites of ROS production [76]. However, data that highlighted mitochondrial complexes activity in HD-affected skeletal muscle and heart are ambiguous. Indeed, no alterations of the mitochondrial electron transport chain activity were found in the skeletal muscle of 12-weeks-old R6/2 mice or skeletal muscle of 15-months-old HdhQ111 knock-in mice [77,78]. On the other hand, other analyses, performed on muscles of R6/2 mice at late stages of disease progression, reported a significant reduction of the activity of the complex IV or both, complex I and IV [6,79]. Our current study underlined the opposite tendency. We found that mitochondria of the soleus of the R6/1 mouse model, despite reduced complex II and no changes in IV activity, exhibited elevated complex I activity. A similar tendency in complex I respiration we found in the mitochondria isolated from R6/1 mice hearts. Moreover, in contrast to mitochondria isolated from skeletal muscle the improvement of complex II respiration was noted. While Kojer et al. highlighted no changes in mitochondrial oxidative chain complexes in R6/2 mice hearts [6]. We suggested that such complex I hyperactivation may be the cause of observed increased ROS production and thus HD cardiac and skeletal muscle mitochondria dysfunction. Nevertheless, more mechanistic studies on isolated mitochondria or cardiac and muscle cells are needed to clarify the origin of this activation.

There is a study indicating that rosiglitazone treatment rapidly decreases the activities of mitochondrial respiratory complex I and III without modifying complex II in liver mitochondria, and in this way diminished intracellular ROS production [80]. Rabol et al. showed that skeletal muscle mitochondria isolated from patients with diabetes type 2 supplemented with rosiglitazone for 12 weeks also exerted an inhibitory effect on complex I [81]. It is in the line with our data, highlighting that rosiglitazone treatment of HD mouse model leads to reduction of complex I activity in mitochondria isolated from skeletal muscle and heart. That may suppress the ROS overproduction and improve cardiac and skeletal muscle functionality. Indeed we also found the improvement of total plasma antioxidant status (TAOS), one of the oxidative balance indicators in rosiglitazone-treated mice, which suggested its correction [82]. It is known that the evaluation of this parameter was applied to reveal oxidative balance instead of measuring different oxidant and antioxidant molecules individually [83,84]. We noted also the reduction in TAOS in R6/1 relative to control mice. It supports the paradigms mentioned above regarding the presence of oxidative stress in HD mouse models. Interestingly, recently Yildiz et al. also underlined a significant reduction in TAOS in patients with Alzheimer’s disease and other CNS diseases [85]. Unfortunately, no data were available from HD patients.

5. Conclusions and Perspectives

Several earlier studies highlighted the usefulness of anti-diabetic drugs (primarily peroxisome proliferator-activated receptors (PPARs) agonists, like rosiglitazone) in the treatment of patients with other neurodegenerations such as Alzheimer’s disease [86]. Hervas et al. (2017) noted that administration of metformin—another anti-diabetic drug that stimulates adenosine monophosphate-activated protein kinase (AMPK)—was associated with better cognitive function and motor function improvement in Huntington’s disease (HD) patients [87]. Although, usage of an AMPK activator in HD might be beneficial only in the first stages of the disease where AMPK is downregulated, not in advanced stages where AMPK is already upregulated in HD-affected tissues (brain as well as skeletal
muscles and heart) [30,87–89]. PPAR agonists could be more effective since PPAR and its signaling are downregulated in all HD stages [90].

Despite numerous basic studies highlighting the role of PPAR agonists in HD, more clinical studies are needed to clarify its possible usage in HD treatment. These studies should especially identify whether non-diabetic or diabetic HD patients would benefit more, and identify side effects. Our research conducted on non-diabetic R6/1 HD mouse models indicated that even in non-diabetic HD patients, such treatment could be considered.

6. Limitations

It has to be mentioned that grip strength evaluated in this study does not selectively identify a change in skeletal muscle function. Besides skeletal muscle functionality, the central nervous system (CNS), motor neurons, and neuromuscular transmission also contribute to overall grip strength. Thus, enhancement of this parameter after peroxisome proliferator-activated receptors (PPARs) agonist treatment might be related to the improvement of the CNS and its signaling (peripheral nerve functionality enhancement), while cardiac function recovery after rosiglitazone therapy might be linked with the improvement of the heart–brain axis. Nonetheless, dysfunction of peripheral cells was noted also in vitro studies, suggesting that the pathogenesis of Huntington’s disease (HD) in the heart and skeletal muscle may be independent of the CNS [1,91].

It is well known that skeletal muscle can continue to generate force at low adenosine-5'-triphosphate (ATP) levels. Indeed, it has been shown that maximum skeletal muscle force does not decrease until the concentration of ATP is less than 20 µM [92]. Moreover, skeletal muscle force was shown to increase by 10% in 0.5–1 mM of ATP concentration [93,94]. Changes in ATP levels might also affect muscle function by altering the SR Ca2+ ATPase (SERCA pump) and excitation-contraction coupling [95]. Interestingly, there is work showing altered excitation-contraction coupling in HD-affected muscle [96,97].

Furthermore, maximal skeletal muscle force occurs when blood flow is blocked to the muscle due to the contraction. These adaptations gave the ability of a skeletal muscle to continue its function in extreme metabolic conditions. Thus, as observed in our research, improved skeletal muscle glucose metabolism and total adenine nucleotides pool after rosiglitazone treatment may not result in improved skeletal muscle contractility parameters. On the other hand, our previous research indicated that the skeletal muscle of HD mice models was characterized by progressive impairment of the contractile and significant loss of motor units, accompanied by diminished skeletal muscle glucose oxidation and deterioration in energy metabolism [17]. Thus, one may conclude that improvement of these parameters in HD-affected skeletal muscle may have a positive impact on its functionality; however, more experimental studies are needed to clarify this assumption.

Despite these limitations, our study for the first time highlighted that the treatment of the HD mouse model with PPAR-γ agonists like rosiglitazone induces alterations in skeletal muscle and heart metabolism that may contribute to enhanced grip strength and improvement of cardiac function. Thus, these molecules might be an interesting therapeutic tool to treat not only neurodegeneration but also cardiomyopathy and myopathy linked to HD.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells11172662/s1, Figure S1: Reduced grip strength in R6/1 mice in comparison to healthy controls (C57BL/6J), Figure S2: Deterioration of heart function in R6/1 mice model, Figure S3: Representative echocardiograms from R6/1 mice model (A.) and R6/1 mice model treated with rosiglitazone (B.), Figure S4: Blood glucose and serum-free fatty acids concentration in R6/1 mice (HD) as well as HD with Rosiglitazone (HD+ Rosiglitazone), Figure S5: Representative Seahorse XF assays on coupled cardiac and skeletal muscle mitochondria isolated from HD and control mice, Figure S6: Representative Seahorse XF assays on isolated cardiac mitochondria of HD and control mice, Figure S7: Representative Seahorse XF assays on isolated soleus muscle mitochondria of HD and control mice., Figure S8: Mitochondrial functionality parameters (citrate
synthase and ROS) in hearts and skeletal muscle of HD and control mice, Figure S9: Total plasma antioxidant status in C57Bl (control) and R6/1 (HD) mice.

Author Contributions: Conceptualization, M.T. and R.T.S.; Formal analysis, M.T., A.B., P.M., M.P., O.K., P.J., A.J. and K.P.; Funding acquisition, M.T. and R.T.S.; Investigation, M.T., A.B., P.M., P.J., A.J. and K.P.; Methodology, M.T., A.B., P.M., O.K., P.J. and A.J.; Supervision, G.W., E.M.S. and R.T.S.; Writing—original draft, M.T. and R.T.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the National Science Centre in Poland (number 2016/23/B/NZ4/03877 and number 2015/17/N/NZ4/02841).

Institutional Review Board Statement: All experimental protocols used in this study were approved by the local commission for animal experiments in Bydgoszcz, Poland (Resolution 43/2015).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Walker, F.O. Huntington’s Disease. *Lancet* 2007, 369, 218–228. [CrossRef]
2. Davies, S.W.; Turmaine, M.; Cozens, B.A.; DiFiglia, M.; Sharp, A.H.; Ross, C.A.; Scherzinger, E.; Wanker, E.E.; Mangiarini, L.; Bates, G.P. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation. *Cell* 1997, 90, 537–548. [CrossRef]
3. Moffitt, H.; McPhail, G.D.; Woodman, B.; Hobbs, C.; Bates, G.P. Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-in Mouse Model of Huntington’s Disease. *PLoS ONE* 2009, 4, e8025. [CrossRef] [PubMed]
4. Li, S.H.; Li, X.J. Huntingtin-Protein Interactions and the Pathogenesis of Huntington’s Disease. *Trends Genet.* 2004, 20, 146–154. [CrossRef]
5. Li, S.H.; Li, X.J. Huntingtin-Protein Interactions and the Pathogenesis of Huntington’s Disease. *Trends Genet.* 2004, 20, 146–154. [CrossRef]
6. Kojer, K.; Hering, T.; Bazenet, C.; Weiss, A.; Herrmann, F.; Taanman, J.W.; Orth, M. Huntingtin Aggregates and Mitochondrial Pathology in Skeletal Muscle but Not Heart of Late-Stage R6/2 Mice. *J. Huntington’s Dis.* 2019, 8, 145–159. [CrossRef]
7. Mielcarek, M.; Inuabasi, L.; Bondulich, M.K.; Muller, T.; Osborne, G.F.; Franklin, S.A.; Smith, D.L.; Neueder, A.; Rosinski, J.; Rattray, I.; et al. Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington’s Disease. *PLoS Genet* 2014, 10, e1004550. [CrossRef]
8. Busse, M.E.; Hughes, G.; Wiles, C.M.; Rosser, A.E. Use of Hand-Held Dynamometry in the Evaluation of Lower Limb Muscle Strength in People with Huntington’s Disease. *J. Neurol.* 2008, 255, 1534–1540. [CrossRef]
9. Hansska, D.J.; Lavine, L.; Lanska, M.J.; Schoenberg, B.S. Huntington’s Disease Mortality in the United States. *Neurology* 1988, 38, 769–772. [CrossRef]
10. Chiu, E.; Alexander, L. Causes of Death in Huntington’s Disease. *Med. J. Aust.* 1982, 1, 153. [CrossRef]
11. van der Burg, J.M.; Bjorkqvist, M.; Brundin, P. Beyond the Brain: Widespread Pathology in Huntington’s Disease. *Lancet Neurol.* 2009, 8, 765–774. [CrossRef]
12. Ribchester, R.R.; Thomson, D.; Wood, N.I.; Hinks, T.; Gillingwater, T.H.; Wishart, T.M.; Court, F.A.; Morton, A.J. Progressive Abnormalities in the Motor Unit of a Fast-Twitch Lower Limb Skeletal Muscle Model of Huntington’s Disease. *Eur. J. Neurosci.* 2004, 20, 3092–3114. [CrossRef] [PubMed]
13. Romer, S.H.; Metzger, S.; Peraza, K.; Wright, M.C.; Jobe, D.S.; Song, L.S.; Rich, M.M.; Foy, B.D.; Talmadge, R.J.; Voss, A.A. A Mouse Model of Huntington’s Disease Shows Altered Ultrastructure of Transverse Tubules in Skeletal Muscle Fibers. *J. Gen. Physiol.* 2021, 153, e202012637. [CrossRef] [PubMed]
14. Valadão, P.A.C.; de Aragão, B.C.; Andrade, J.N.; Magalhães-Gomes, M.P.S.; Foureaux, G.; Joviano-Santos, J.V.; Nogueira, J.C.; Machado, T.C.G.; de Jesus, I.C.G.; Nogueira, J.M.; et al. Abnormalities in the Motor Unit of a Fast-Twitch Lower Limb Skeletal Muscle in Huntington’s Disease. *ASN Neuro* 2019, 11, 1759091419886212. [CrossRef] [PubMed]
15. Valadão, P.A.C.; de Aragão, B.C.; Andrade, J.N.; Magalhães-Gomes, M.P.S.; Foureaux, G.; Joviano-Santos, J.V.; Nogueira, J.C.; Ribeiro, F.M.; Tapia, J.C.; Guatimosim, C. Muscle Atrophy Is Associated with Cervical Spinal Motoneuron Loss in BACHD Mouse Model for Huntington’s Disease. *Eur. J. Neurosci.* 2017, 45, 785–796. [CrossRef]
16. Strand, A.D.; Aragaki, A.K.; Shaw, D.; Bird, T.; Holton, J.; Turner, C.; Tapscott, S.J.; Tabrizi, S.J.; Schapira, A.H.; Kooperberg, C.; et al. Gene Expression in Huntington’s Disease Skeletal Muscle: A Potential Biomarker. *Hum. Mol. Genet.* 2005, 14, 1863–1876. [CrossRef]
17. Mielcarek, M.; Toczek, M.; Smeets, C.J.; Franklin, S.A.; Bondulich, M.K.; Jolinon, N.; Muller, T.; Ahmed, M.; Dick, J.R.; Piotrowska, I.; et al. HDAC4-Myogenin Axis As an Important Marker of HD-Related Skeletal Muscle Atrophy. *PLoS Genet.* 2015, 11, e1005021. [CrossRef]

18. Wood, N.I.; Sawiak, S.J.; Buoniconti, G.; Niu, Y.; Kane, A.D.; Carpenter, T.A.; Giussani, D.A.; Morton, A.J. Direct Evidence of Progressive Cardiac Dysfunction in a Transgenic Mouse Model of Huntington’s Disease. *J. Huntingt. Dis.* 2012, 1, 57–64. [CrossRef]

19. Kiriazis, H.; Jennings, N.L.; Davern, P.; Lambert, G.; Su, Y.; Pang, T.; Du, X.; La Greca, L.; Head, G.A.; Hannan, A.J.; et al. Neurocardiac Dysregulation and Neurogenic Arrhythmias in a Transgenic Mouse Model of Huntington’s Disease. *J. Physiol.* 2012, 590, 5845–5860. [CrossRef]

20. Mielcarek, M. Huntington’s Disease Is a Multi-System Disorder. *Rare Dis.* 2015, 3, e1058464. [CrossRef]

21. Mochel, F.; Haller, R.G. Energy Deficit in Huntington Disease: Why It Matters. *Journal of Clinical Investigation* 2011, 121, 493–499. [CrossRef]

22. Jodeiri Farshbaf, M.; Ghaedi, K. Huntington’s Disease and Mitochondria. *Neurotox Res* 2017, 32, 518–529. [CrossRef] [PubMed]

23. Gines, S.; Seong, I.S.; Fossale, E.; Ivanova, E.; Trettel, F.; Gusella, J.F.; Wheeler, V.C.; Persichetti, F.; MacDonald, M.E. Specific Progressive CAMP Reduction Implicated in Patients and Asymptomatic Mutation Carriers of Huntington’s Disease Knock-in Mice. *Hum. Mol. Genet.* 2003, 12, 497–508. [CrossRef]

24. Mochel, F.; Durant, B.; Meng, X.; O’Callaghan, J.; Yu, H.; Brouillet, E.; Wheeler, V.C.; Humbert, S.; Schiffrmann, R.; Durr, A. Early Alterations of Brain Cellular Energy Homeostasis in Huntington Disease Models. *J. Biol. Chem.* 2012, 287, 1361–1370. [CrossRef]

25. Seong, I.S.; Ivanova, E.; Lee, J.M.; Choo, Y.S.; Fossale, E.; Anderson, M.; Gusella, J.F.; Laramie, J.M.; Myers, R.H.; Lesort, M.; et al. HD CAG Repeat Implies a Dominant Property of Huntingtin in Mitochondrial Energy Metabolism. *Hum. Mol. Genet.* 2005, 14, 2871–2880. [CrossRef] [PubMed]

26. Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C.N.; Tanese, N.; Krainc, D. Transcriptional Repression of PGC-1alpha by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. *Cell* 2006, 127, 59–69. [CrossRef] [PubMed]

27. Zielonka, D.; Piotrowska, I.; Marcinkowski, J.T.; Mielcarek, M. Skeletal Muscle Pathology in Huntington’s Disease. *Front. Physiol.* 2014, 5, 380. [CrossRef]

28. Saft, C.; Zange, J.; Andrich, J.; Muller, K.; Lindenberg, K.; Landwehrmeyer, B.; Vorgerd, M.H.; Przuntek, H.; Schols, L. Mitochondrial Impairment in Patients and Asymptomatic Mutation Carriers of Huntington’s Disease. *Mov. Disord.* 2005, 20, 674–679. [CrossRef]

29. Lodi, R.; Schapira, A.H.V.; Manners, D.; Styles, P.; Wood, N.W.; Taylor, D.J.; Warner, T.T. Abnormal in Vivo Skeletal Muscle Energy Metabolism in Huntington’s Disease and Dentatorubropallidoluysian Atrophy. *Ann. Neurol.* 2000, 48, 72–76. [CrossRef]

30. Toczek, M.; Zielonka, D.; Zukowska, P.; Marcinkowski, J.T.; Slominska, E.; Isalan, M.; Smolenski, R.T.; Mielcarek, M. An Impaired Metabolism of Nucleotides Underpins a Novel Mechanism of Cardiac Remodeling Leading to Huntington’s Disease Related Cardiomyopathy. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2016, 1862, 2147–2157. [CrossRef]

31. Zielonka, D.; Piotrowska, I.; Marcinkowski, J.T.; Mielcarek, M. Metabolism in Huntington's Disease: Still a Relevant Mechanism? *Pharmacol. Ther.* 2021, 207, 12251. [CrossRef]

32. Wagner, N.; Wagner, K.D. Peroxisome Proliferator-ACTivated Receptors and the Hallmarks of Cancer. *Cells* 2022, 11, 2432. [CrossRef] [PubMed]

33. Wagner, K.D.; Wagner, N. Peroxisome Proliferator-ACTivated Receptor Beta/Delta (PPARβ/δ) Acts as Regulator of Metabolism Linked to Multiple Cellular Functions. *Pharmacol. Ther.* 2010, 125, 423–435. [CrossRef] [PubMed]

34. Dickey, A.S.; Pineda, V.V.; Tsunemi, T.; Liu, P.P.; Miranda, H.C.; Gilmore-Hall, S.K.; Lomas, N.; Sampat, K.R.; Buttergeit, A.; Torres, M.J.M.; et al. PPAR-δ Is Repressed in Huntington’s Disease, Is Required for Normal Neuronal Function and Can be Targeted Therapeutically. *Nat. Med.* 2016, 22, 37–45. [CrossRef]

35. Jin, J.; Albertz, J.; Guo, Z.; Peng, Q.; Rudow, G.; Broncoso, J.C.; Ross, C.A.; Duan, W. Neuroprotective Effects of PPAR-γ Agonist Rosiglitazone in N171-82Q Mouse Model of Huntington’s Disease. *J. Neurochem.* 2013, 125, 410–419. [CrossRef]

36. Tomczyk, M.; Braczkó, A.; Jablonska, P.; Mika, A.; Przyborowski, K.; Jedrzejewska, A.; Krol, O.; Kus, F.; Sledzinski, T.; Chłopicki, S.; et al. Enhanced Muscle Strength in Dyslipidemic Mice and Its Relation to Increased Capacity for Fatty Acid Oxidation. *Int. J. Mol. Sci.* 2021, 22, 12251. [CrossRef]

37. Zukowska, P.; Kutryb-Zajac, B.; Jasztal, A.; Toczek, M.; Zabielska, M.; Borkowski, T.; Khalpey, Z.; Smolenski, R.T.; Slominska, E.M. Deletion of CD73 in Mice Leads to Aortic Valve Dysfunction. *Biochim. Biophys. Acta Mol. Basis Dis.* 2017, 1863, 1464–1472. [CrossRef]

38. Tomczyk, M.; Ołkowicz, M.; Slominska, E.M.; Smolenski, R.T. High Throughput Procedure for Comparative Analysis of in Vivo Cardiac Glucose or Amino Acids Use in Cardiovascular Pathologies and Pharmacological Treatments. *Metabolites* 2021, 11, 497. [CrossRef]

39. Rogers, G.W.; Brand, M.D.; Petrosyan, S.; Ashok, D.; Elorza, A.A.; Ferrick, D.A.; Murphy, A.N. High Throughput Microplate Respiratory Measurements Using Minimal Quantities of Isolated Mitochondria. *PLoS One* 2011, 6, e21746. [CrossRef]

40. Cichońska, D.; Kłosa, D.; Kłosińska, E.M.; Kochańska, B.; Świertlik, D.; Ochocińska; J.; Kusiak, A. Influence of Electronic Cigarettes on Antioxidant Capacity and Nucleotides Metabolites in Saliva. *Toxins* 2021, 9, 263. [CrossRef]

41. McNumty, P.H.; Cline, G.W.; Whiting, J.M.; Shulman, G.I. Regulation of Myocardial [13C]Glucose Metabolism in Conscious Rats. *Am. J. Physiol.-Heart Circ. Physiol.* 2000, 279, H375–H381. [CrossRef] [PubMed]
42. Olkowicz, M.; Tomczyk, M.; Debski, J.; Tyrankiewicz, U.; Przyborowski, K.; Borkowski, T.; Zabiecka-Kaczorowska, M.; Szupryczynska, N.; Kochan, Z.; Smeda, M.; et al. Enhanced Cardiac Hypoxic Injury in Atherogenic Dyslipidaemia Results from Alterations in the Energy Metabolism Pattern. *Metabolism*. 2021, 114, 154400. [CrossRef] [PubMed]

43. Palee, S. PPARγ Activator, Rosiglitazone: Is It Beneficial or Harmful to the Cardiovascular System? *World J. Cardiol*. 2011, 3, 144. [CrossRef] [PubMed]

44. Chaturvedi, R.K.; Adhihetty, P.; Shukla, S.; Hennessy, T.; Calingasan, N.; Yang, L.; Starkov, A.; Kiaei, M.; Cannella, M.; et al. PPARγ Activator, Rosiglitazone Activation of PPARγ-Dependent Signaling Is Neuroprotective in Mutant Huntington-Expressing Cells. *Exp. Cell Res.* 2015, 338, 183–193. [CrossRef] [PubMed]

45. Chiang, M.C.; Cheng, Y.C.; Nicol, C.J.; Lin, K.H.; Yen, C.H.; Chen, S.J.; Huang, R.N. Rosiglitazone Activation of PPARγ-Dependent Mitochondrial Biogenesis Exerts Widespread Beneficial Effects in a Transgenic Mouse Model of Huntington’s Disease. *Hum. Mol. Genet.* 2012, 21, 1124–1137. [CrossRef] [PubMed]

46. Han, L.; Shen, W.J.; Bittner, S.; Kraemer, F.B.; Azhar, S. PPARs: Regulators of Metabolism and as Therapeutic Targets in Cardiovascular Disease. Part II: PPAR-β/δ and PPAR-γ. *Future Cardiol.* 2017, 13, 279–296. [CrossRef]

47. Hasson, F.E.; Sakr, H.I.; Mohie, P.M.; Suliman, H.S.; Mohamed, A.S.; Attia, M.H.; Eid, D.M. Rosiglitazone Improves Skeletal Muscle Mitochondrial Function in Risperidone-Induced Fibromyalgia Rat Model. *Ann. Med.* 2021, 53, 1033–1041. [CrossRef]

48. Chaturvedi, R.K.; Adhihetty, P.; Shukla, S.; Hennessy, T.; Calingasan, N.; Yang, L.; Starkov, A.; Kiaei, M.; Cannella, M.; et al. Impaired PGC-1α-1x Activity in Muscle in Huntington’s Disease. *Hum. Mol. Genet.* 2009, 18, 3048–3065. [CrossRef] [PubMed]

49. Johri, A.; Calingasan, N.Y.; Hennessey, T.M.; Sharma, A.; Yang, L.; Wille, E.; Chandra, A.; Beal, M.F. Pharmacologic Activation of Mitochondrial Biogenesis Exerts Widespread Beneficial Effects in a Transgenic Mouse Model of Huntington’s Disease. *Hum. Mol. Genet.* 2012, 21, 1124–1137. [CrossRef] [PubMed]

50. Yue, T.L.; Chen, J.; Bao, W.; Narayanan, P.K.; Bril, A.; Jiang, W.; Lysko, P.G.; Gu, J.L.; Boyce, R.; Zimmerman, D.M.; et al. Inhibition of Brain Citrate Synthase Activity in an Animal Model of Sepsis. *Arch. Physiol. Biochem.* 2017, 125, 179–188. [CrossRef]

51. Janani, C.; Ranjitha Kumari, B.D. PPAR Gamma Gene—A Review. *Diabetes Metab. Synth. Clin. Res. Rev.* 2015, 9, 46–50. [CrossRef]

52. Kim, S.H.; Abbasi, F.; Chu, J.W.; McLaughlin, T.L.; Lamendola, C.; Polonsky, K.S.; Reaven, G.M. Rosiglitazone Reduces Glucose-Stimulated Insulin Secretion Rate and Increases Insulin Clearance in Nondiabetic, Insulin-Resistant Individuals. *Arch. Physiol. Biochem.* 2007, 113, 244–257. [CrossRef]

53. Khandoudi, N.; Delerive, P.; Berrebi-Bertrand, I.; Buckingham, R.E.; Staels, B.; Bril, A. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-γ Inhibitor, Protects the Heart from Ischemia/Reperfusion Injury. *Diabetes 2002, 51, 1507–1514. [CrossRef] [PubMed]

54. Han, L.; Shen, W.J.; Bittner, S.; Kraemer, F.B.; Azhar, S. Rosiglitazone Improves Skeletal Muscle Mitochondrial Function in Risperidone-Induced Fibromyalgia Rat Model. *Ann. Med.* 2021, 53, 1033–1041. [CrossRef]

55. Yue, T.L.; Chen, J.; Bao, W.; Narayanan, P.K.; Bril, A.; Jiang, W.; Lysko, P.G.; Gu, J.L.; Boyce, R.; Zimmerman, D.M.; et al. Inhibition of Brain Citrate Synthase Activity in an Animal Model of Sepsis. *Arch. Physiol. Biochem.* 2017, 125, 179–188. [CrossRef]

56. Yeh, T.C.; Hsu, Y.C.; Chen, C.M.; Wang, S.H.; Wang, C.H.; Hsu, C.H.; Chiang, M.C.; Cheng, Y.C.; Nicol, C.J.; Lin, K.H.; Yen, C.H.; Chen, S.J.; Huang, R.N. Rosiglitazone Activation of PPARγ-Dependent Signaling Is Neuroprotective in Mutant Huntington-Expressing Cells. *Exp. Cell Res.* 2015, 338, 183–193. [CrossRef] [PubMed]

57. Johri, A.; Calingasan, N.Y.; Hennessey, T.M.; Sharma, A.; Yang, L.; Wille, E.; Chandra, A.; Beal, M.F. Pharmacologic Activation of Mitochondrial Biogenesis Exerts Widespread Beneficial Effects in a Transgenic Mouse Model of Huntington’s Disease. *Hum. Mol. Genet.* 2012, 21, 1124–1137. [CrossRef] [PubMed]

58. Han, L.; Shen, W.J.; Bittner, S.; Kraemer, F.B.; Azhar, S. PPARs: Regulators of Metabolism and as Therapeutic Targets in Cardiovascular Disease. Part II: PPAR-β/δ and PPAR-γ. *Future Cardiol.* 2017, 13, 279–296. [CrossRef]

59. Janani, C.; Ranjitha Kumari, B.D. PPAR Gamma Gene—A Review. *Diabetes Metab. Synth. Clin. Res. Rev.* 2015, 9, 46–50. [CrossRef]

60. Hansson, O.; Petersen, Å.; Leist, M.; Nicotera, P.; Castilho, R.F.; Brundin, P. Transgenic Mice Expressing a Huntington’s Disease Activator, Rosiglitazone: Is It Beneficial or Harmful to the Cardiovascular System? *Future Cardiol.* 2017, 13, 279–296. [CrossRef]

61. Janani, C.; Ranjitha Kumari, B.D. PPAR Gamma Gene—A Review. *Diabetes Metab. Synth. Clin. Res. Rev.* 2015, 9, 46–50. [CrossRef]

62. Mihm, M.J.; Amann, D.M.; Schanbacher, B.L.; Altschuld, R.A.; Bauer, J.A.; Hoyt, K.R. Cardiac Dysfunction in the R6/2 Mouse Model of Huntington’s Disease. *Neurobiol. Dis.* 2007, 29, 257–268. [CrossRef] [PubMed]

63. Bozzi, M.; Sciandra, F. Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease. *Int. J. Mol. Sci.* 2020, 21, 8314. [CrossRef]

64. Strum, J.C.; Shehee, R.; Virley, D.; Richardson, J.; Mattie, M.; Sellep, P.; Ghosh, S.; Nock, C.; Saunders, A.; Roses, A. Rosiglitazone Induces Mitochondrial Biogenesis in Mouse Brain. *J. Alzheimer’s Dis.* 2007, 11, 45–51. [CrossRef]

65. Wilson-Fritch, L.; Nicoloro, S.; Chouinard, M.; Lazar, M.A.; Chui, P.C.; Leszky, J.; Straubhaar, J.; Czech, M.P.; Corvera, S. Mitochondrial Remodeling in Adipose Tissue Associated with Obesity and Treatment with Rosiglitazone. *J. Clin. Investig.* 2004, 114, 1281–1289. [CrossRef]

66. Scaini, G.; Rachi, N.; Benedet, J.; Ferreira, G.K.; Teodorak, B.P.; Comim, C.M.; de Constantino, L.S.; Vuolo, F.; Constantino, L.C.; Quevedo, J.; et al. Inhibition of Brain Citrate Synthase Activity in an Animal Model of Sepsis. *Rev. Bras. Ter. Intensiva* 2011, 23, 158–163. [CrossRef]
67. Intihar, T.A.; Martinez, E.A.; Gomez-Pastor, R. Mitochondrial Dysfunction in Huntington’s Disease; Interplay between HSF1, P53 and PGC-1a Transcription Factors. *Front. Cell. Neurosci.* 2019, 13, 103. [CrossRef]

68. Ismailoglu, I.; Chen, Q.; Popowski, M.; Yang, L.; Gross, S.S.; Brivanlou, A.H. Huntingtonin Protein Is Essential for Mitochondrial Metabolism, Bioenergetics and Structure in Murine Embryonic Stem Cells. *Dev. Biol.* 2014, 391, 230–240. [CrossRef]

69. Kumar, A.; Ratan, R.R. Oxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly. *J. Huntingt. Dis.* 2016, 5, 217–237. [CrossRef]

70. Ayala-Peña, S. Role of Oxidative DNA Damage in Mitochondrial Dysfunction and Huntington’s Disease Pathogenesis. *Free. Radic. Biol. Med.* 2013, 62, 102–110. [CrossRef]

71. Hands, S.; Sajjad, M.U.; Newton, M.J.; Wytttenbach, A. In Vitro and in Vivo Aggregation of a Fragment of Huntingtonin Protein Directly Causes Free Radical Production. *J. Biol. Chem.* 2011, 286, 44512–44520. [CrossRef] [PubMed]

72. Zuo, L.; Best, T.M.; Roberts, W.J.; Diaz, P.T.; Wagner, F.D. Characterization of Reactive Oxygen Species in Diaphragm. *Acta Physiol. 2015*, 213, 700–710. [CrossRef] [PubMed]

73. Zuo, L.; Pannell, B.K. Redox Characterization of Functioning Skeletal Muscle. *Front. Physiol.* 2015, 6, 338. [CrossRef] [PubMed]

74. He, F.; Zuo, L. Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases. *Int. J. Mol. Sci.* 2015, 16, 27770–27780. [CrossRef]

75. Joviano-Santos, J.V.; Santos-Miranda, A.; Botelho, A.F.M.; de Jesus, I.C.G.; Andrade, J.N.; de Oliveira Barreto, T.; Magalhaes-Gomes, M.P.S.; Valadão, P.A.C.; dos Cruz, J.S.; Melo, M.M.; et al. Increased Oxidative Stress and CaMKII Activity Contribute to Electro-Mechanical Defects in Cardiomyocytes from a Murine Model of Huntington’s Disease. *FEBS J.* 2019, 286, 110–123. [CrossRef]

76. Zhao, R.Z.; Jiang, S.; Zhang, L.; Yu, Z. Bin. Mitochondrial Electron Transport Chain, ROS Generation and Uncoupling (Review). *Int. J. Mol. Med.* 2019, 44, 3–15. [CrossRef]

77. Tabrizi, S.J.; Workman, J.; Hart, P.E.; Mangiarini, L.; Mahal, A.; Bates, G.; Cooper, J.M.; Schapira, A.H.V. Mitochondrial Dysfunction and Free Radical Damage in the Huntington R6/2 Transgenic Mouse. *Ann. Neurol.* 2000, 47, 80–86. [CrossRef]

78. Buck, E.; Zügel, M.; Schumann, U.; Merz, T.; Gump, A.M.; Witting, A.; Steinacker, J.M.; Landwehrmeyer, G.B.; Weydt, P.; Calzia, E.; et al. High-Resolution Respirometry of Fine-Needle Muscle Biopsies in Pre-Manifest Huntington’s Disease Expansion Mutation Carriers Shows Normal Mitochondrial Respiratory Function. *PLoS ONE* 2017, 12, e0175248. [CrossRef]

79. Giza, Z.; Zimenkova, I.; Blackman, D.; Fornes, D.; Fornes, D.; Gómez-Manrique, R.P. Metformin Ameliorates the Neurobehavioral Deficits in Huntington’s Disease Mouse Model. *Front. Physiol.* 2017, 8, 127. [CrossRef]

80. Short, B. AMPK Amplifies Huntington’s Disease. *J. Cell Biol.* 2011, 194, 2247–2262. [CrossRef]

81. Rabøl, R.; Boushel, R.; Almdal, T.; Hansen, C.N.; Ploug, T.; Haugaard, S.B.; Prats, C.; Madsbad, S.; Dela, F. Opposite Effects of Pioglitazone and Rosiglitazone on Mitochondrial Respiration in Skeletal Muscle of Patients with Type 2 Diabetes. *Diabetes, Obes. Metab.* 2010, 12, 806–814. [CrossRef]

82. Zuo, L.; Kozlović, J.; Pannell, B.K. Oxidative Stress and Huntington’s Disease Pathogenesis. *Int. J. Mol. Sci.* 2015, 16, 27770–27780. [CrossRef]

83. Ismailoglu, I.; Chen, Q.; Popowski, M.; Yang, L.; Gross, S.S.; Brivanlou, A.H. Huntingtonin Protein Is Essential for Mitochondrial Metabolism, Bioenergetics and Structure in Murine Embryonic Stem Cells. *Dev. Biol.* 2014, 391, 230–240. [CrossRef]

84. Erel, O. A Novel Automated Direct Measurement Method for Total Antioxidant Capacity Using a New Generation, More Stable [CrossRef]

85. Erel, O. A New Automated Colorimetric Method for Measuring Total Oxidant Status. *Clin. Biochem.* 2005, 38, 1103–1111. [CrossRef] [PubMed]

86. Erel, O. A Novel Automated Direct Measurement Method for Total Antioxidant Capacity Using a New Generation, More Stable ABTS Radical Cation. *Clin. Biochem.* 2004, 37, 277–285. [CrossRef] [PubMed]

87. Yildiz, Z.; Eren, N.; Orcun, A.; Münvever Gokyigit, F.; Turgay, F.; Gündoğdu Celebi, L. Serum Apelin-13 Levels and Total Oxidant/Antioxidant Status of Patients with Alzheimer’s Disease. *Aging Med.* 2021, 4, 201–205. [CrossRef] [PubMed]

88. Rizvi, S.M.D.; Shaikh, S.; Waseem, S.M.A.; Shakil, S.; Abuzeinadah, A.M.; Biswas, D.; Tabrez, S.; Ashraf, G.M.; Kamal, M.A. Role of Anti-Diabetic Drugs as Therapeutic Agents in Alzheimer’s Disease. *EXCLI J.* 2015, 14, 684. [CrossRef]

89. Hervás, D.; Fornés-Ferrer, V.; Gómez-Escibano, A.P.; Sequedo, M.D.; Peiró, C.; Millán, J.M.; Vázquez-Manrique, R.P. Metformin Intake Associates with Better Cognitive Function in Patients with Huntington’s Disease. *PLoS ONE* 2017, 12, e0179283. [CrossRef]

90. Mielcarek, M.; Smolencki, R.T.; Isalan, M. Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington’s Disease Mouse Model. *Front. Physiol.* 2017, 8, 127. [CrossRef]

91. Short, B. AMPK Amplifies Huntington’s Disease. *J. Cell Biol.* 2011, 194, 2247–2262. [CrossRef]

92. Chiang, M.C.; Chen, C.M.; Lee, M.R.; Chen, H.W.; Chen, H.M.; Wu, Y.S.; Hung, C.H.; Kang, J.J.; Chang, C.P.; Chang, C.; et al. Modulation of Energy Deficiency in Huntington’s Disease via Activation of the Peroxisome Proliferator-Activated Receptor Gamma. *Hum. Mol. Genet.* 2010, 19, 4043–4058. [CrossRef]

93. Dutka, T.L.; Mollica, J.P.; Lamb, G.D. Differential Effects of Peroxynitrite on Contractile Protein Properties in Fast- and Slow-Twitch Skeletal Muscle Fibers of Rat. *J. Appl. Physiol.* 2011, 110, 705–716. [CrossRef] [PubMed]
94. Godt, R.E.; Nosek, T.M. Changes of Intracellular Milieu with Fatigue or Hypoxia Depress Contraction of Skinned Rabbit Skeletal and Cardiac Muscle. *J. Physiol.* **1989**, *412*, 155–180. [CrossRef]

95. Allen, D.G.; Lamb, G.D.; Westerblad, H. Skeletal Muscle Fatigue: Cellular Mechanisms. *Physiol. Rev.* **2008**, *88*, 287–332. [CrossRef]

96. Braubach, P.; Orynbayev, M.; Andronache, Z.; Hering, T.; Landwehrmeyer, G.B.; Lindenberg, K.S.; Melzer, W. Altered Ca$^{2+}$ Signaling in Skeletal Muscle Fibers of the R6/2 Mouse, a Model of Huntington’s Disease. *J. Gen. Physiol.* **2014**, *144*, 393–413. [CrossRef]

97. Dridi, H.; Liu, X.; Yuan, Q.; Reiken, S.; Yehya, M.; Sittenfeld, L.; Apostolou, P.; Buron, J.; Sicard, P.; Matecki, S.; et al. Role of Defective Calcium Regulation in Cardiorespiratory Dysfunction in Huntington’s Disease. *JCI Insight* **2020**, *5*, e140614. [CrossRef]